Abbvie Inc [NYSE: ABBV] plunged by -$0.99 during the normal trading session on while it closed the day at $178.00. The company report on February 28, 2024 at 12:05 AM that AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the
Abbvie Inc [NYSE: ABBV] price surged by 0.92 percent to reach at $1.61. The company report on February 22, 2024 at 8:05 AM that AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology. Collaboration to leverage AbbVie’s therapeutic area expertise and
Abbvie Inc [NYSE: ABBV] closed the trading session at $173.29. The company report on February 12, 2024 at 7:37 AM that AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie’s
Abbvie Inc [NYSE: ABBV] closed the trading session at $171.26. The company report on February 2, 2024 at 7:36 AM that AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results. Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted
Abbvie Inc [NYSE: ABBV] gained 0.62% or 1.01 points to close at $164.92 with a heavy trading volume of 3815759 shares. The company report on January 25, 2024 at 7:30 PM that AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing
© 2024, Powered by Smart TechOne
